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ORIGINAL ARTICLE
Effectiveness of Foot Orthoses Versus Rocker-Sole
Footwear for First Metatarsophalangeal Joint
Osteoarthritis: Randomized Trial
HYLTON B. MENZ,1 MARIA AUHL,1 JADE M. TAN,1 PAZIT LEVINGER,2 EDWARD RODDY,3 AND
SHANNON E. MUNTEANU1
Objective. To compare the effectiveness of prefabricated foot orthoses to rocker-sole footwear in reducing foot pain in
people with first metatarsophalangeal (MTP) joint osteoarthritis (OA).
Methods. Participants (n5102) with first MTP joint OA were randomly allocated to receive individualized, prefabri-
cated foot orthoses or rocker-sole footwear. The primary outcome measure was the pain subscale on the Foot Health
Status Questionnaire (FHSQ) at 12 weeks. Secondary outcome measures included the function, footwear, and general
foot health subscales of the FHSQ; the Foot Function Index; severity of pain and stiffness at the first MTP joint; per-
ception of global improvement; general health status; use of rescue medication and co-interventions to relieve pain;
physical activity; and the frequency of self-reported adverse events.
Results. The FHSQ pain subscale scores improved in both groups, but no statistically significant difference between
the groups was observed (adjusted mean difference 2.05 points, 95% confidence interval [95% CI] 23.61, 7.71;
P5 0.477). However, the footwear group exhibited lower adherence (mean6SD total hours worn 2876193 versus
4486 234; P < 0.001), were less likely to report global improvement in symptoms (39% versus 62%; relative risk [RR]
0.63, 95% CI 0.41, 0.99; P50.043), and were more likely to experience adverse events (39% versus 16%; RR 2.47, 95%
CI 1.12, 5.44; P50.024) compared to the orthoses group.
Conclusion. Prefabricated foot orthoses and rocker-sole footwear are similarly effective at reducing foot pain in peo-
ple with first MTP joint OA. However, prefabricated foot orthoses may be the intervention of choice due to greater
adherence and fewer associated adverse events.
INTRODUCTION
Osteoarthritis (OA) of the first metatarsophalangeal (MTP)
joint is the most common form of foot OA. Radiographic
changes within this joint are observed in up to 35% of people
age .35 years (1), while the population prevalence of
symptomatic radiographic first MTP joint OA has recently
been estimated as 7.8% in people age.50 years (2). The con-
dition is characterized by symptoms of joint pain and stiff-
ness, formation of a dorsal exostosis, and progressive
reduction in range of motion of first MTP joint dorsiflexion
with increasing radiographic severity (3). As a consequence
of these changes, 72% of those affected report associated loco-
motor disability (2), and the condition has been shown to
have a detrimental impact on health-related quality of life (4).
Several treatments have been proposed for first MTP
joint OA, including physical therapies, antiinflammatory
medications, intraarticular injections, foot orthoses, foot-
wear modifications, and surgery (5). However, the evi-
dence for the effectiveness of these treatments is limited,
with the most recent systematic review identifying only 1
very small, low-quality trial of 2 physical therapy pro-
grams with a short (4-week) followup (6). Since the publi-
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cation of this review, 1 additional trial has been con-
ducted, which found that intraarticular viscosupplemen-
tation with hyaluronan was no more effective than a
placebo injection after 3 months of followup (7). Clearly,
there is a need for additional well-designed trials into
nonsurgical interventions for first MTP joint OA.
Biomechanical factors are thought to contribute to first
MTP joint OA (8), suggesting that mechanical interven-
tions may hold some promise as an effective treatment for
this condition. One of the most commonly used interven-
tions is foot orthoses, which are thought to decrease first
MTP joint pain by allowing the first metatarsal to plantar-
flex during the propulsive phase of gait, thereby minimiz-
ing dorsal joint compression (9). A similar effect may also
be obtained using a footwear modification known as a
rocker-sole, which allows the body’s center of mass to
“roll over” the base of support, reducing the need for first
MTP joint dorsiflexion. However, evidence to support the
effectiveness of foot orthoses for first MTP joint OA is lim-
ited to case reports (10,11) and 1 case series study (12).
Similarly, the effectiveness of rocker-sole footwear is
largely anecdotal, with only 1 small case series suggesting
that rocker-sole footwear was effective when combined
with intraarticular corticosteroid injection (13).
Given the prevalence and impact of first MTP joint OA
and the lack of evidence for existing interventions, the
objective of this study was to compare the effectiveness of
prefabricated foot orthoses to rocker-sole footwear in
reducing foot pain in people with first MTP joint OA.
MATERIALS AND METHODS
Trial design. The trial was prospectively registered
with the Australian New Zealand Clinical Trials Registry
(12613001245785). The La Trobe University Human
Ethics Committee provided ethical approval (13-003) and
all participants provided written informed consent prior
to enrollment. The full trial protocol has been published
previously (14). The study design was a parallel-group
randomized trial comparing 2 interventions: prefabricated
foot orthoses versus commercially available rocker-sole
footwear (Masai Barefoot Technology [MBT]). Participants
were informed that they would receive either the foot
orthoses or rocker-sole footwear (i.e., they were not
blinded to their group allocation). Due to the nature of the
intervention, research staff administering the treatments
were not blinded to group allocation. However, the fol-
lowup assessment of outcome measures was via self-
completion questionnaires returned by mail, and staff
entering outcome measure data and conducting statistical
analyses were blinded.
Participants. Between February and October 2014 we
recruited participants via 1) radio advertisements; 2)
advertisements placed in local newspapers, magazines,
and social media; 3) posters placed at health care facili-
ties, gymnasiums, senior citizens’ centers, fun runs, and
markets, and 4) mail-out advertisements to patients
attending the La Trobe University Health Sciences clinic
and to local podiatry clinics.
To be included in the study, participants had to 1) be
age $18 years, 2) report having pain in the first MTP joint
on most days for at least 12 weeks, 3) report having pain
rated at least 20 mm on a 100-mm visual analog scale
(VAS), 4) have ,648 of dorsiflexion range of motion of the
first MTP joint (15), 5) have pain upon palpation of the
dorsal aspect of the first MTP joint, 6) be able to walk
household distances (.50 meters) without the aid of a
walker, crutches, or cane, 7) be willing to attend the
Health Sciences Clinic at La Trobe University (Melbourne,
Victoria, Australia) on 2 occasions and have their foot
radiographed, 8) be willing to not receive additional inter-
ventions (such as physical therapy, foot orthoses, shoe
modifications, intraarticular injections, or surgery) for the
first MTP joint pain during the course of the study, and 9)
be willing to discontinue taking all medications to relieve
pain at their first MTP joint (analgesics and nonsteroidal
antiinflammatory medications, except paracetamol up to 4
gm/day) for at least 14 days prior to the baseline assess-
ment and during the study period.
Exclusion criteria included 1) pregnancy; 2) previous
surgery on the first MTP joint; 3) significant deformity of
the first MTP joint including hallux valgus (grade of 3 or 4
scored using the Manchester Scale) (16,17); 4) presence of
1 or more conditions within the foot or ankle that, in the
opinion of the investigators, could confound pain and
functional assessments of the first MTP joint, such as
metatarsalgia, plantar fasciitis, predislocation syndrome,
Achilles tendinopathy, or degenerative joint disease (oth-
er than the first MTP joint), determined by a podiatrist; 5)
presence of any systemic inflammatory condition, such as
inflammatory arthritis, rheumatoid arthritis, ankylosing
spondylitis, psoriatic arthritis, reactive arthritis, septic
arthritis, acute pseudogout, gout, or any other connective
tissue disease; 6) any medical condition that, in the opin-
ion of the investigators, made the participant unsuitable
for inclusion (e.g., severe progressive chronic disease,
malignancy, clinically important pain in a part of the mus-
culoskeletal system other than the first MTP joint, or fibro-
myalgia); 7) cognitive impairment (defined as a score of
,7 on the Short Portable Mental Status Questionnaire)
(18); 8) intraarticular injections into the first MTP joint in
the previous 6 months; 9) currently wearing contoured
foot orthoses (although flat insoles were permitted); 10)
Significance & Innovations
 This is the first randomized trial to compare the
effectiveness of foot orthoses and rocker-sole
shoes in people with first metatarsophalangeal
(MTP) joint osteoarthritis (OA).
 Both interventions were similarly effective at
reducing foot pain.
 Adherence was lower and adverse events more
common in the rocker-sole footwear group.
 Foot orthoses may be the preferred intervention
for first MTP joint OA.
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currently wearing specialized footwear (footwear that has
been custom-made or “prescribed” by a health care practi-
tioner); 11) currently wearing shoes that would not be able
to accommodate a foot orthosis; or 12) older adults with a
history of recurrent falls (defined as 2 or more falls in the
previous 12 months), as there is some evidence that
rocker-sole shoes may have short-term detrimental effects
on balance (19).
Randomization. Permuted block randomization with
random block sizes, stratified by sex, was undertaken using
an interactive voice response telephone service provided
by the National Health and Medical Research Council Clin-
ical Trials Centre at the University of Sydney, New South
Wales, Australia to ensure allocation concealment (14).
Clinical and radiographic assessment. All assess-
ments and interventions were performed at the La Trobe
University Health Sciences Clinic, Melbourne, Victoria,
Australia. At baseline, participants underwent a clinical
assessment including measurements of height, weight, and
body mass index, foot posture (using the Foot Posture
Index [FPI]) (20), passive non–weight-bearing dorsiflexion
range of motion at the first MTP joint (21) and observation
to determine the presence or absence of pain on palpation,
a dorsal exostosis, joint effusion, pain during motion, a
hard-end feel when the joint was fully dorsiflexed, and
crepitus during movement. The reliability of these assess-
ments has previously been documented (15).
The presence of radiographic first MTP joint OA was
determined at baseline using a radiographic atlas developed
by Menz et al (22). The atlas incorporates weight-bearing
dorsoplantar and lateral radiographs to document the pres-
ence of OA based on observations of osteophytes and joint
space narrowing. Osteophytes were recorded as absent
(score 0), small (score 1), moderate (score 2), or severe (score
3). Joint space narrowing was recorded as none (score 0),
definite (score 1), severe (score 2), or joint fusion (score 3).
Radiographic OA using this atlas is defined as a score of 2
or more for osteophytes or joint space narrowing on either
dorsoplantar and lateral views. The atlas has been shown to
have good to excellent intra- and interrater reliability for
grading first MTP joint OA (Œ5 0.64–0.95) (22).
Interventions. The prefabricated foot orthoses group
received a pair of foot orthoses (Vasyli Customs Medium
Density, Vasyli Medical) that were modified using a simi-
lar approach to that described by Welsh et al (12). All
orthoses were full length, but were modified by adding a
cut-out section beneath the first metatarsal and trimming
the distal edge to the level of the second to fifth toe sulci
(for details of the foot orthoses, see Figure 1, ref. 23). In
participants with pronated feet (defined as an FPI score of
.7 [24]), full length, 48 medial (varus) wedges were
applied to the underside of the foot orthoses until there
was a reduction in the FPI score of at least 2 points (12).
The wedge was gradually bevelled so that it extended to
the proximal margin of the cut-out section beneath the
first metatarsal. The rocker-sole footwear group was pro-
vided with a pair of rocker-sole shoes (MBT, Mahuta or
Matwa models). These shoes are characterized by a round-
ed sole in the anteroposterior direction and a soft, cush-
ioned heel (for details of the rocker-sole shoes, see Figure
2, ref. 23). Across the full size range, the radius of curva-
ture of the MBT is on average 33 cm overall, 18 cm at the
forefoot, 43 cm at the midfoot, and 11 cm at the heel (25).
Fitting of the shoes was undertaken by trained assessors
using the Brannock Device. All participants received an
information handout that outlined the appropriate use
and care of their orthoses or footwear.
Outcome measures. The primary outcome measure was
the foot pain domain of the Foot Health Status Question-
naire (FHSQ) (26), measured at baseline and at 4, 8, and
12 weeks. The FHSQ is a foot-specific, health-related qual-
ity of life outcome measure consisting of 13 questions that
assess 4 domains of foot health, including pain, function,
footwear, and general foot health. Questions within each
domain are scored using a Likert response format, with an
output score produced ranging from 0 to 100, with a score
of 100 indicating optimum foot health and a score of 0
indicating very poor foot health. The FHSQ has been
shown to have a high degree of internal consistency
(Cronbach’s a50.88) and test–retest reliability (intraclass
correlation coefficient 0.86) (26), and is a widely recom-
mended outcome measure in clinical trials of rheumato-
logic foot disorders (27). Participants treated for bilateral
symptoms were asked to describe symptoms of their most
painful foot. If both feet were equally painful, the right
foot was selected as the index foot.
Secondary outcome measures included 1) the function
domain of the FHSQ, measured at baseline and at 4, 8, and
12 weeks; 2) the Foot Function Index Revised (Short Form)
(28) measured at baseline and 12 weeks; 3) severity of pain
at the first MTP joint while walking over a flat surface and
during rest over the last week (each via a 100-mm VAS, mea-
sured at baseline and at 4, 8, and 12 weeks; 4) duration and
severity of stiffness at the first MTP joint after first awaken-
ing in the morning, during the last week (via a 100-mm
VAS), measured at baseline and at 4, 8, and 12 weeks; 5)
severity of stiffness after sitting, lying, or resting later in the
day, during the last week (via a 100-mm VAS), measured at
baseline and at 4, 8, and 12 weeks; 6) global change in symp-
toms using a 15-point Likert scale (where 75 a very great
deal better, 65 a great deal better, 55 a good deal better,
45moderately better, 35 somewhat better, 25 a little bet-
ter, 15 about the same, hardly any better at all, 05no
change, 215 about the same, hardly any worse at all,
225 a little worse,235 somewhat worse,245moderately
worse,255 a good deal worse,265 a great deal worse, and
275 a very great deal worse, with a dichotomized score of
$4 representing improvement), measured at 12 weeks; 7)
health status (using the Short-Form 12, version 2 question-
naire) (29), measured at baseline and 12 weeks; 8) use of
paracetamol rescue medication (number of participants and
mean consumption) and cointerventions to relieve pain at
the first MTP joint, documented with a monthly diary
throughout the 12-week study period; 9) the frequency and
type of self-reported adverse events (defined as an unwanted
event that may or may not be related to the treatment) col-
lected at 4 weekly intervals throughout the 12-week study
period; and 10) the Incidental and Planned Activity Ques-
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tionnaire, a self-report questionnaire that covers the frequen-
cy and duration of several levels of planned and incidental
physical activity (30), measured at baseline and 12 weeks.
To maximize response to the postal questionnaire outcome
measures, we sent e-mails or letters after 1 week to nonres-
ponders, and then followed up with up to 3 attempted con-
tacts by telephone and/or e-mail over a 2-week period.
Sample size. The sample size for the study was deter-
mined using an a priori power analysis based on the pri-
mary outcome measure: the pain domain of the FHSQ
(26). We have previously determined that the minimal
important difference for this measure in people with foot
pain is 13 points (31). Using an SD of 19 (derived from our
recent trial [7]), a power level of 0.8, an alpha level of
0.05, and accounting for a dropout rate of 15%, we deter-
mined that a sample size of 80 participants (i.e., approxi-
mately 40 per group) was required.
Statistical analysis. Statistical analysis was undertaken
using SPSS, version 22.0, using the intent-to-treat principle
for all randomized participants (32). Multiple imputation
Figure 1. Flow of participants through study. MTPJ5 first metatarsophalangeal joint.
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was used to replace missing data using 5 iterations, with
age, baseline scores, and group allocation as predictors
(33). The exception was the use of co-interventions, rescue
medication, and adverse events, where no data substitution
was applied. Continuously scored outcome measures were
analyzed using analysis of covariance (ANCOVA), with
baseline scores and intervention group entered as indepen-
dent variables (34). Dichotomously scored outcome meas-
ures were compared using relative risk (RR), and number
needed to treat/harm (NNH). To avoid overtesting and to
minimize the risk of Type I error associated with serial
measurements, statistical analysis of the effectiveness of
the interventions specifically focused on the change in out-
come measures between baseline and 12 weeks (35,36).
RESULTS
Participant characteristics. Figure 1 shows the flow of
participants through the study. The sample consisted of
102 participants (45 men and 57 women), ages 22–78
years (mean6SD age 56.86 11.1 years). Fifty-two partici-
pants were allocated to the orthoses group and 50 to the
footwear group. Participants in the 2 groups had similar
baseline characteristics (Table 1). Four participants in the
footwear group withdrew consent after randomization and
did not receive their allocated intervention. Of these, 2
could not tolerate the shoes, 1 had very large feet that
could not be accommodated in the available size range,
and 1 withdrew on advice from their chiropractor. Shortly
after commencing the study, the MBT shoe we used (the
Mahuta model) was discontinued by the company and
replaced with the “Matwa” model, resulting in 4 partici-
pants receiving the Mahuta and 42 receiving the Matwa.
However, both models had the same sole curvature and
only differed slightly in relation to the aesthetics of the
upper. Two participants in the orthoses group had pro-
nated feet (FPI .7), so had varus wedges applied to their
orthoses according to the prespecified protocol (14).
Participant retention and intervention adherence. By
the 12-week followup, there were 5 dropouts in the orthoses
group (1 withdrew as they could not tolerate the orthoses,
and 4 were lost to followup) and 5 dropouts in the footwear
group (2 withdrew as they could not tolerate the footwear,
and 3 were lost to followup), giving completion rates of
90% and 89%, respectively. Participants in the orthoses
group reported wearing their intervention for a greater
Table 1. Participant characteristics at baseline*
Orthoses
group
(n5 52)
Footwear
group
(n5 46)
Demographics and anthropometrics
Age, years 57.1611.1 56.5611.1
Female, no. (%) 29 (55.8) 28 (60.9)
Height, cm 166.06 8.9 166.36 8.3
Weight, kg 80.5614.9 78.5613.3
Body mass index, kg/m2 29.26 4.8 28.46 4.5
General health
SF-12 physical 44.1610.7 45.06 9.7
SF-12 mental 55.86 8.1 51.96 9.0
Total physical activity, hours/week 17.5614.6 15.4611.4
Clinical features
Pain duration, median (range) months 33 (4–360) 30 (6–240)
Foot Posture Index, mean6SD (range) 3.06 2.4 (22–11) 3.46 2.2 (22–10)
First MTP joint ROM, degrees 39.8612.5 40.5613.0
Pain on palpation, no. (%) 52 (100) 46 (100)
Palpable dorsal exostosis, no. (%) 50 (96.2) 45 (97.8)
Joint effusion, no. (%) 17 (33.3) 16 (34.8)
Pain on motion of first MTP joint, no. (%) 49 (94.2) 41 (91.1)
Hard-end feel when dorsiflexed, no. (%) 47 (90.4) 39 (84.8)
Crepitus, no. (%) 35 (67.3) 30 (65.2)
Radiographic features, no. (%)†
Dorsal osteophytes 50 (96.2) 39 (84.8)
Dorsal joint space narrowing 43 (82.7) 39 (84.8)
Lateral osteophytes 42 (80.8) 39 (84.8)
Lateral joint space narrowing 45 (86.5) 38 (82.6)
Radiographic first MTP joint OA‡ 37 (71.2) 33 (76.7)
* Values are the mean6SD unless indicated otherwise. SF-125Short Form 12 health survey; MTP5metatarsophalangeal;
ROM5 range of motion; OA5osteoarthritis.
† Score .0 using atlas in ref. 22.
‡ At least one score of 2 for osteophytes or joint space narrowing from either view, using case definition from atlas in ref.
22.
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Table 2. Primary and secondary outcome measures at baseline and followup*
Orthoses
group
(n5 52)
Footwear
group
(n5 46)
Adjusted mean difference
(95% CI)† P
FHSQ pain domain (1–100 points)‡
Baseline 56.7619.2 51.5620.3
4 weeks 68.4615.8 64.5617.5
8 weeks 73.2615.6 67.9617.9
12 weeks 73.6616.8 73.7614.8 2.05 (23.61, 7.71) 0.477
FHSQ function domain (1–100 points)‡
Baseline 70.8622.0 67.4625.5
4 weeks 79.0620.8 76.9620.9
8 weeks 81.5618.1 77.4617.3
12 weeks 82.7618.6 80.5616.6 20.24 (24.95, 4.47) 0.920
FFI pain (1–100 points)‡
Baseline 40.5617.0 41.9618.7
12 weeks 42.4612.7 41.0612.5 21.80 (26.14, 2.55) 0.418
FFI stiffness (1–100 points)‡
Baseline 33.4619.5 37.1623.4
12 weeks 41.1613.0 42.0616.3 20.25 (25.59, 5.08) 0.926
FFI difficulty (1–100 points)‡
Baseline 37.6624.5 40.0625.0
12 weeks 43.7614.8 46.3616.0 1.69 (23.11, 6.49) 0.489
FFI overall (1–100 points)‡
Baseline 37.0618.8 39.6620.7
12 weeks 42.5611.3 43.1613.8 20.39 (24.14, 3.37) 0.840
Pain severity while walking (0–100 mm)§
Baseline 46.4621.9 47.5622.4
4 weeks 27.0620.6 30.1621.9
8 weeks 24.6619.9 24.8618.6
12 weeks 23.0620.7 20.3616.0 22.89 (210.40, 4.61) 0.450
Pain severity at rest (0–100 mm)§
Baseline 32.4624.8 34.4625.4
4 weeks 20.5618.7 21.7620.0
8 weeks 15.8616.7 17.8618.5
12 weeks 17.0619.6 16.4619.2 21.27 (28.31, 5.78) 0.724
Stiffness severity in morning (0–100 mm)§
Baseline 32.1626.3 39.3625.2
4 weeks 19.5615.9 26.4625.1
8 weeks 15.2614.5 20.5621.2
12 weeks 18.9619.7 22.7622.9 0.95 (27.93, 9.82) 0.832
Stiffness severity later in day (0–100 mm)§
Baseline 34.0627.0 37.6625.4
4 weeks 17.8616.7 25.4624.4
8 weeks 17.3617.1 19.8620.1
12 weeks 18.1620.0 15.8617.8 22.99 (210.53, 4.59) 0.441
SF-12 physical (1–100 points)‡
Baseline 44.1610.7 45.069.7
12 weeks 47.169.2 46.769.7 20.98 (23.81, 1.86) 0.499
SF-12 mental (1–100 points)‡
Baseline 55.868.1 51.969.0
12 weeks 52.369.6 52.069.6 20.32 (23.93, 3.29) 0.862
Total physical activity (hours/week)
Baseline 17.5614.6 15.4611.4
12 weeks 21.9616.7 16.6612.1 24.46 (210.10, 1.17) 0.120
* Values are the mean6SD unless indicated otherwise. 95% CI5 95% confidence interval; FHSQ5Foot Health Status Questionnaire; FFI5Foot
Function Index; SF-125Short Form 12 health survey.
† Adjusted for baseline score and intervention group using analysis of covariance.
‡ Higher scores indicate better function.
§ Higher scores indicate worse symptoms.
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number of hours than the footwear group (mean6SD total
hours worn over study period: 4486 238 versus 2876192;
P, 0.001).
Primary outcome. Table 2 shows the mean6SD scores
and adjusted mean differences (95% confidence intervals
[95% CIs]) between groups for the FHSQ pain domain at
baseline and at 4, 8, and 12 weeks followup. Both groups
demonstrated an increase in the FHSQ pain domain score
(17 points in the orthoses group and 22 points in the foot-
wear group), which is indicative of improved foot health.
However, there was no difference between the groups at
the 12-week followup (ANCOVA-adjusted mean differ-
ence of 2.05 points; 95% CI 23.61, 7.71; P5 0.477).
Secondary outcomes. Table 2 shows the mean6SD
scores and adjusted mean differences (95% CIs) between
groups for the secondary outcome measures (FHSQ func-
tion domain, FFI, pain and stiffness, SF-12, and physical
activity levels). There were no differences between the
groups at the 12-week followup for any of these measures.
However, at the completion of the study, the perception of
global improvement, defined as at least moderate improve-
ment (score $4) on the 15-point Likert scale, was lower in
the footwear group (39% versus 62%; RR 0.63, 95% CI
0.41, 0.99; P5 0.043). The NNH was 5 (95% CI 2.3, 43.9),
meaning that 1 in every 5 participants treated with foot-
wear had an unsuccessful outcome compared to those
receiving orthoses.
Use of cointerventions and adverse events. There was
no difference in the proportion of participants reporting
use of cointerventions between the orthoses and footwear
groups (18% versus 15%; RR 0.87, 95% CI 0.33, 2.28;
P5 0.770) and no difference in the proportion of partici-
pants who reported consuming rescue medications
between the orthoses and footwear groups (24% versus
28%; RR 1.15, 95% CI 0.56, 2.36; P5 0.696).
Adverse events are reported in Table 3. The most com-
monly reported adverse events were new episodes of back
or lower extremity pain (n5 44), blisters (n5 5), discom-
fort associated with the intervention (n5 5), and impaired
balance (n55). Participants in the footwear group were
more likely to report at least 1 adverse event (39% versus
16%; RR 2.47, 95% CI 1.12, 5.44; P50.024; NNH 5, 95%
CI 2.4, 23.1) and were more likely to report a new episode
of low back pain during the study than the orthoses group
(17% versus 4%; RR 4.52, 95% CI 1.01, 20.22; P5 0.048;
NNH 8, 95% CI 3.9, 71.0).
DISCUSSION
This is the first randomized trial to evaluate the effective-
ness of mechanical interventions in reducing foot pain in
people with first MTP joint OA. We found that both the
orthoses and footwear groups demonstrated an increase in
the FHSQ pain domain score (indicative of an improve-
ment in foot health), but there was no difference between
the groups at the 12-week followup. However, the foot-
wear group reported lower adherence, were less likely to
report at least moderate improvement in symptoms, and
were more likely to experience adverse events, particu-
larly new-onset low back pain, compared to the orthoses
group. Taken together, these findings suggest that prefabri-
cated foot orthoses may be the preferred intervention in
the treatment of first MTP joint OA.
The primary outcome measure (FHSQ pain domain)
increased in both groups at the 12-week followup by 17
points in the orthoses group and 22 points in the footwear
group. This change in FHSQ scores exceeds the minimal
important difference for this measure (13 points) (31). How-
ever, because this is not a controlled trial, we cannot be cer-
tain of the extent to which the observed changes are true
therapeutic effects as opposed to placebo effects, Haw-
thorne effects, regression to the mean, or natural resolution.
We originally intended to provide sham orthoses (37) as
the comparator to the rocker-sole footwear; however, this
was considered by our ethics committee to be withholding
usual care and was not permitted (14). Nevertheless, our
analysis of the biomechanical effects of these interventions
at the baseline appointment indicated that both interven-
tions were similarly effective at reducing peak pressure
under the first MTP joint compared to participants’ usual
Table 3. Adverse events reported during the study*
Orthoses group
(n552)
Footwear group
(n5 46) RR (95% CI) P
Reported at least 1 adverse event 7 (15.6) 15 (38.5) 2.47 (1.12, 5.44) 0.024†
Blisters 2 (3.8) 3 (6.5) 1.34 (0.45, 4.00) 0.442
Discomfort 2 (3.8) 3 (6.5) 1.34 (0.45, 4.00) 0.442
Impaired balance 1 (1.9) 4 (8.7) 2.74 (0.47, 15.98) 0.145
Experienced fall during trial 5 (11.1) 4 (10.3) 0.92 (0.27, 3.20) 0.900
Developed new back/lower extremity pain during trial 31 (68.9) 28 (73.7) 1.07 (0.81, 1.41) 0.629
Low back 2 (3.8) 8 (17.4) 4.52 (1.01, 20.22) 0.048†
Hip 1 (1.9) 1 (2.2) 1.13 (0.07, 17.57) 0.930
Knee 4 (7.7) 3 (6.5) 0.85 (0.20, 3.59) 0.823
Lower leg 6 (11.5) 6 (13.0) 1.13 (0.39, 3.26) 0.821
Foot/ankle 22 (42.3) 20 (43.5) 1.03 (0.65, 1.62) 0.907
* Values are the number (percentage) unless indicated otherwise. RR5 relative risk; 95% CI5 95% confidence interval.
† Significantly higher risk in footwear group compared to orthoses group.
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footwear (23), which may at least partly explain the similar
improvement in symptoms we observed at followup.
Adherence varied markedly between the 2 groups. We
found that the footwear group wore their shoes for an aver-
age of 287 hours in total throughout the 12-week study peri-
od, compared to 448 hours for the orthoses group. This
finding was not unexpected, as due to the pronounced sole
curvature, the MBT shoes have a characteristic appearance
that may not have been aesthetically acceptable to all par-
ticipants. Furthermore, because many of our participants
were of working age, workplace attire constraints may have
created a barrier to wearing the allocated footwear. Low
adherence is a well-recognized problem with footwear
intervention studies and has been attributed to the unique
role of footwear as both an item of clothing and a health-
related intervention (38). In contrast, the orthoses are trans-
ferrable, can be accommodated in most types of footwear,
and are hidden from view, which may have facilitated
them being worn more frequently. These observations sug-
gest that orthoses may be a more practical intervention.
However, given that the change in FHSQ pain scores was
similar between the groups despite marked differences in
adherence, it is possible that the rocker-sole shoes have the
potential for greater effectiveness if barriers to adherence
could be overcome.
Adverse events were more common in the footwear
group. Most of these were relatively minor (such as blis-
ters and general discomfort); however, the increased risk
of new-onset low back pain is a notable finding. We can-
not be certain that the footwear caused the low back pain
reported by these participants, nor whether these cases
were merely transient episodes reflecting a habituation
period associated with wearing the shoes. Nevertheless,
biomechanical studies have reported increased thoracic
motion and lumbar erector spinae muscle activity when
standing (39) and a trend toward increased activity of glu-
teus medius when walking (40) when wearing MBT shoes.
These changes have generally been interpreted as poten-
tially beneficial for people with low back pain, as they are
thought to represent a “training” effect on pelvic and spi-
nal muscles responsible for postural control (41). How-
ever, evidence pertaining to the effectiveness of MBT
shoes in the treatment of low back pain is equivocal
(42,43). It is also possible that such changes may be detri-
mental to those who do not have low back pain, and may
explain the higher rate of new-onset low back pain we
observed in the footwear group.
Key strengths of this study include the use of well-
validated outcome measures, high participant retention,
and broad generalizability. However, our findings need to
be interpreted in the context of several methodological
limitations. First, as previously discussed, this was not a
controlled trial, so we cannot be certain that the observed
changes in participant-reported outcome measures are
true therapeutic effects. Second, it was not possible to
blind participants to their intervention. Third, not all par-
ticipants met the case definition for radiographic OA
described by Menz et al (22), which requires a score of 2
or more for osteophytes or joint space narrowing on either
dorsoplantar and lateral views. In order to minimize costs
and radiation exposure, we did not use radiographs for eli-
gibility screening, and instead used the clinical diagnostic
tests described by Zammit et al (15) to identify partici-
pants with likely OA. In our sample, this clinical model
was sensitive but not specific, meaning that 28 partici-
pants included in the trial did not meet the case definition
according to Menz et al (22). Nevertheless, these partici-
pants all showed at least some radiographic changes and
exhibited other cardinal signs of first MTP joint OA. Final-
ly, we used a specific model of MBT shoe and prefabri-
cated orthosis, so it is unclear whether our findings can be
generalized to other types of rocker-sole shoes or orthoses
that may have different biomechanical effects.
In summary, this randomized trial has shown that prefab-
ricated foot orthoses and rocker-sole footwear are similarly
effective at reducing foot pain in people with first MTP
joint OA. However, the higher adherence and lower rate of
adverse events we observed in the orthoses group suggests
that prefabricated foot orthoses may be the preferred inter-
vention for this condition. Future research should focus on
examining the effectiveness of other types of orthoses and
footwear interventions compared to a sham intervention,
identifying who is most likely to benefit from mechanical
interventions, and determining whether barriers to adher-
ence with rocker-sole footwear can be overcome by
addressing concerns related to aesthetics and comfort.
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